Sagimet biosciences inc.SGMT.US Overview
SGMT Overall Performance
SGMT AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
SGMT Current Performance
-0.66%
Sagimet biosciences inc.
-0.47%
Avg of Sector
-0.64%
S&P500
SGMT Key Information
SGMT Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
SGMT Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
SGMT Profile
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Price of SGMT
SGMT FAQ
When is SGMT's latest earnings report released?
The most recent financial report for Sagimet biosciences inc. (SGMT) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SGMT's short-term business performance and financial health. For the latest updates on SGMT's earnings releases, visit this page regularly.
How much cash does SGMT have?
At the end of the period, Sagimet biosciences inc. (SGMT) held Total Cash and Cash Equivalents of 42.33M, accounting for 0.31 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is SGMT's EPS continuing to grow?
According to the past four quarterly reports, Sagimet biosciences inc. (SGMT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of SGMT?
Sagimet biosciences inc. (SGMT)'s Free Cash Flow (FCF) for the period is -9.1M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 61.54% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of SGMT?
The latest valuation data shows Sagimet biosciences inc. (SGMT) has a Price-To-Earnings (PE) ratio of -5.25 and a Price/Earnings-To-Growth (PEG) ratio of 0.14. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.